{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:28:42Z","timestamp":1726759722646},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T00:00:00Z","timestamp":1361404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>JTT-305\/MK-5442 is a calcium-sensing receptor (CaSR) allosteric antagonist being investigated for the treatment of osteoporosis. JTT-305\/MK-5442 binds to CaSRs, thus preventing receptor activation by Ca2+. In the parathyroid gland, this results in the release of parathyroid hormone (PTH). Sharp spikes in PTH secretion followed by rapid returns to baseline are associated with bone formation, whereas sustained elevation in PTH is associated with bone resorption. We have developed a semimechanistic, nonpopulation model of the time-course relationship between JTT-305\/MK-5442 and whole plasma PTH concentrations to describe both the secretion of PTH and the kinetics of its return to baseline levels. We obtained mean concentration data for JTT-305\/MK-5442 and whole PTH from a multiple dose study in U.S. postmenopausal women at doses of 5, 10, 15, and 20\u2009mg. We hypothesized that PTH is released from two separate sources: a reservoir that is released rapidly (within minutes) in response to reduction in Ca2+ binding, and a second source released more slowly following hours of reduced Ca2+ binding. We modeled the release rates of these reservoirs as maximum pharmacologic effect (Emax) functions of JTT-305\/MK-5442 concentration. Our model describes both the dose-dependence of PTH time of occurrence for maximum drug concentration (Tmax) and maximum concentration of drug (Cmax), and the extent and duration of the observed nonmonotonic return of PTH to baseline levels following JTT-305\/MK-5442 administration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.1900","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T19:40:50Z","timestamp":1361475650000},"page":"1830-1836","source":"Crossref","is-referenced-by-count":10,"title":["A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305\/MK-5442 in humans"],"prefix":"10.1093","volume":"28","author":[{"given":"Antonio","family":"Cabal","sequence":"first","affiliation":[{"name":"Early Stage Development (ESD) - Modeling and Simulations, Merck and Co.Upper Gwynedd, PAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khamir","family":"Mehta","sequence":"additional","affiliation":[{"name":"Applied Computer Science and Mathematics, Merck and Co.West Point, PAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S","family":"Ross","sequence":"additional","affiliation":[{"name":"School of Mathematical Sciences, Rochester Institute of TechnologyRochester, NYUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv P","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Department of Mechanical and Industrial EngineeringUniversity of Massachusetts, AmherstAmherst, MAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Comisar","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics\/Pharmacodynamics (PK\/PD), Merck and Co.West Point, PAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Denker","sequence":"additional","affiliation":[{"name":"Project Leadership Management (PLM) Oncology, Merck and Co.Kenilworth, NJUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhakar M","family":"Pai","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Akros Pharma, Inc.Princeton, NJUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Clinical Development Department, Japan Tobacco, Inc.TokyoJapan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,2,21]]},"reference":[{"key":"2024020318371009400_jbmr1900-bib-0001","first-page":"S40","article-title":"Randomized, single-blinded placebo-controlled study of a novel calcilytic, JTT-305, in patients with postmenopausal osteoporosis","volume":"24","author":"Fukumoto","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024020318371009400_jbmr1900-bib-0002","first-page":"89","article-title":"[Antagonist for calcium-sensing receptor. JTT-305\/MK-5442]","volume":"21","author":"Fukumoto","year":"2011","journal-title":"Clin Calcium."},{"key":"2024020318371009400_jbmr1900-bib-0003","first-page":"S149","article-title":"The effect of JTT-305 (MK-5442), an orally active calcium-sensing receptor antagonist, on calcium metabolism in parathyroidectomized rats","volume":"26","author":"Kimura","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318371009400_jbmr1900-bib-0004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejphar.2011.07.015","article-title":"JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats","volume":"668","author":"Kimura","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"2024020318371009400_jbmr1900-bib-0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/ml100268k","article-title":"Discovery of a potent and short-acting oral calcilytic with pulsatile secretion of parathyroid hormone","volume":"2","author":"Shinagawa","year":"2011","journal-title":"ACS Med Chem Lett."},{"key":"2024020318371009400_jbmr1900-bib-0006","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure","volume":"33","author":"Frolik","year":"2003","journal-title":"Bone."},{"key":"2024020318371009400_jbmr1900-bib-0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jbmr.5650070110","article-title":"Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone","volume":"7","author":"Hock","year":"1992","journal-title":"J Bone Miner Res."},{"key":"2024020318371009400_jbmr1900-bib-0008","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone."},{"key":"2024020318371009400_jbmr1900-bib-0009","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0009-9236(97)90169-7","article-title":"Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers","volume":"61","author":"Schwietert","year":"1997","journal-title":"Clin Pharmacol Ther."},{"key":"2024020318371009400_jbmr1900-bib-0010","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2165\/00003495-200666180-00008","article-title":"Recombinant full-length parathyroid hormone (1-84)","volume":"66","author":"Moen","year":"2006","journal-title":"Drugs."},{"key":"2024020318371009400_jbmr1900-bib-0011","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/jc.2009-0358","article-title":"Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women","volume":"95","author":"Cosman","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318371009400_jbmr1900-bib-0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mbs.2010.04.001","article-title":"A mathematical model of parathyroid hormone response to acute changes in plasma ionized calcium concentration in humans","volume":"226","author":"Shrestha","year":"2010","journal-title":"Math Biosci."},{"key":"2024020318371009400_jbmr1900-bib-0013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/0-387-27530-4_4","volume-title":"Molecular biology of the parathyroid","author":"Yano","year":"2005"},{"key":"2024020318371009400_jbmr1900-bib-0014","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1023\/A:1026570518919","article-title":"Calcium receptor and regulation of parathyroid hormone secretion","volume":"1","author":"Brown","year":"2000","journal-title":"Rev Endocr Metab Disord."},{"key":"2024020318371009400_jbmr1900-bib-0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1523-1755.2001.0590031187.x","article-title":"Recent developments in the management of secondary hyperparathyroidism","volume":"59","author":"Goodman","year":"2001","journal-title":"Kidney Int."},{"key":"2024020318371009400_jbmr1900-bib-0016","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1210\/jc.2006-1832","article-title":"The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion","volume":"92","author":"Joseph","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318371009400_jbmr1900-bib-0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.109.152033","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans","volume":"330","author":"Abraham","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"key":"2024020318371009400_jbmr1900-bib-0018","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1210\/endo.131.6.1446605","article-title":"Individual parathyroid cells exhibit cyclic secretion of parathyroid hormone and chromogranin-A (as measured by a novel sequential hemolytic plaque assay)","volume":"131","author":"Ritchie","year":"1992","journal-title":"Endocrinology."},{"key":"2024020318371009400_jbmr1900-bib-0019","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1021\/js980171q","article-title":"Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena","volume":"87","author":"Sharma","year":"1998","journal-title":"J Pharm Sci."},{"key":"2024020318371009400_jbmr1900-bib-0020","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.31.5.510","article-title":"Diversity of mechanism-based pharmacodynamic models","volume":"31","author":"Mager","year":"2003","journal-title":"Drug Metab Dispos."},{"key":"2024020318371009400_jbmr1900-bib-0021","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020318371009400_jbmr1900-bib-0022","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1677\/jme.0.0290015","article-title":"The search for calcium receptor antagonists (calcilytics)","volume":"29","author":"Nemeth","year":"2002","journal-title":"J Mol Endocrinol."},{"key":"2024020318371009400_jbmr1900-bib-0023","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.bone.2011.03.091","article-title":"Randomized, double-blinded placebo-controlled study of a calcilytic compound, JTT-305, in patients with postmenopausal osteoporosis","volume":"48","author":"Fukumoto","year":"2011","journal-title":"Bone."},{"key":"2024020318371009400_jbmr1900-bib-0024","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1210\/jc.2010-2855","article-title":"The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density","volume":"96","author":"Fitzpatrick","year":"2011","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1900","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/8\/1830\/56563271\/jbmr1900.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/8\/1830\/56563271\/jbmr1900.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:49:03Z","timestamp":1710341343000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/8\/1830-1836\/7598650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,21]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,2,21]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1900","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,8,1]]},"published":{"date-parts":[[2013,2,21]]}}}